Santen Overview

  • Year Founded
  • 1890

Year Founded

  • Status
  • Public

  • Employees
  • 3,744

Employees

  • Stock Symbol
  • 4536

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $9.65
  • (As of Wednesday Closing)

Santen General Information

Description

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Contact Information

Website
www.santen.com
Formerly Known As
Santendo Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Grand Front Osaka Tower A
  • 4-20 Ofuka-cho, Kita-ku
  • Osaka, 530-8552
  • Japan
+81
Primary Industry
Distributors (Healthcare)
Other Industries
Pharmaceuticals
Other Healthcare Technology Systems
Stock Exchange
TKS
Vertical(s)
Manufacturing, TMT
Corporate Office
  • Grand Front Osaka Tower A
  • 4-20 Ofuka-cho, Kita-ku
  • Osaka, 530-8552
  • Japan
+81

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Santen Stock Performance

As of 19-Mar-2025, Santen’s stock price is $9.65. Its current market cap is $3.29B with 341M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.65 $9.52 $8.83 - $13.05 $3.29B 341M 1.41M $0.52

Santen Financials Summary

As of 31-Dec-2024, Santen has a trailing 12-month revenue of $1.99B.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 2,928,027 3,487,490 3,180,889 3,881,872
Revenue 1,993,452 2,089,870 2,061,111 2,370,031
EBITDA 337,039 340,121 87,131 456,966
Net Income 181,540 184,387 (110,414) 242,275
Total Assets 2,536,499 2,878,751 3,160,906 3,768,813
Total Debt 353,053 384,209 445,573 496,166
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Santen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Santen‘s full profile, request access.

Request a free trial

Santen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports tw
Distributors (Healthcare)
Osaka, Japan
3,744 As of 2024

Toyama, Japan
 

Osaka, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Santen Competitors (2)

One of Santen’s 2 competitors is Nichi-Iko Pharmaceutical, a Corporate Backed or Acquired company based in Toyama, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nichi-Iko Pharmaceutical Corporate Backed or Acquired Toyama, Japan
ONO Pharmaceutical Corporation Osaka, Japan
You’re viewing 2 of 2 competitors. Get the full list »

Santen Patents

  • 3,543

    Total Documents Applications and Grants

  • Total Patents Families

  • 1,441

    Granted

  • 414

    Pending

  • Expiring in next 12 mo

Santen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024090835-A Epinastine-containing aqueous composition for improving migration into tissue Pending 23-Dec-2022
JP-2024090829-A Epinastine-containing aqueous pharmaceutical composition to be accommodated in sterilized container Pending 23-Dec-2022
JP-7245383-B1 Method for suppressing decrease in ph of ophthalmic composition containing diquafosol or its salt Active 20-Sep-2022
JP-2024043685-A Method of inhibiting decrease in ph of ophthalmic composition containing diquafosol or salt thereof Pending 20-Sep-2022
JP-2024044960-A Method of inhibiting decrease in ph of ophthalmic composition containing diquafosol or salt thereof Active 20-Sep-2022
To view Santen’s complete patent history, request access »

Santen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Santen Investments & Acquisitions (8)

Santen’s most recent deal was a Later Stage VC with NovaSight for . The deal was made on 07-Dec-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NovaSight 07-Dec-2022 Later Stage VC Therapeutic Devices
Eyevance Pharmaceuticals 16-Sep-2020 Merger/Acquisition Pharmaceuticals
Twenty Twenty Therapeutics 14-Aug-2020 Joint Venture Diagnostic Equipment
Ace Vision 01-Mar-2020 Later Stage VC Other Devices and Supplies
Clearside Biomedical 02-Sep-2014 Early Stage VC Biotechnology
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Santen ESG

Risk Overview

Risk Rating

Updated December, 20, 2024

24.49 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,946

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Pharmaceuticals

Subindustry

of 421

Rank

Percentile

To view Santen’s complete esg history, request access »

Santen Exits (1)

Santen’s most recent exit was on 02-Sep-2014 from Clearside Biomedical. The exit was categorized as with 6 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Clearside Biomedical 02-Sep-2014 Completed
  • 6 buyers
To view Santen’s complete exits history, request access »

Santen Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Santen Ventures Emeryville, CA 2017

Santen FAQs

  • When was Santen founded?

    Santen was founded in 1890.

  • Where is Santen headquartered?

    Santen is headquartered in Osaka, Japan.

  • What is the size of Santen?

    Santen has 3,744 total employees.

  • What industry is Santen in?

    Santen’s primary industry is Distributors (Healthcare).

  • Is Santen a private or public company?

    Santen is a Public company.

  • What is Santen’s stock symbol?

    The ticker symbol for Santen is 4536.

  • What is the current stock price of Santen?

    As of 19-Mar-2025 the stock price of Santen is $9.65.

  • What is the current market cap of Santen?

    The current market capitalization of Santen is $3.29B.

  • What is Santen’s current revenue?

    The trailing twelve month revenue for Santen is $1.99B.

  • Who are Santen’s competitors?

    Nichi-Iko Pharmaceutical and ONO Pharmaceutical are competitors of Santen.

  • What is Santen’s annual earnings per share (EPS)?

    Santen’s EPS for 12 months was $0.52.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »